IME4 Antibody

What is IME4 and how does it relate to METTL3?

IME4 is a reported synonym of the METTL3 gene, which encodes methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit. This protein plays critical roles in DNA damage pathways and forebrain radial glial cell differentiation among other biological functions. The human version of IME4 has a canonical amino acid length of 580 residues and a molecular weight of approximately 64.5 kilodaltons, although two isoforms have been identified. IME4 is classified as a member of the MT-A70-like protein family and localizes in both the nucleus and cytoplasm of cells .

When designing experiments using IME4 antibodies, researchers should consider the specific isoform they wish to target and verify the epitope recognition region of their selected antibody. For investigations specifically targeting one isoform, custom antibodies against unique regions may be necessary. Confirmation of antibody specificity against recombinant protein standards representing both isoforms is highly recommended before proceeding with experimental applications.

What are the primary applications for IME4 antibodies in research?

IME4 antibodies are primarily used for Western Blot (WB) and Enzyme-Linked Immunosorbent Assay (ELISA) applications across multiple research models . These applications enable the detection and quantification of IME4 protein in various biological samples, supporting research into m6A RNA methylation mechanisms and pathways.

For Western Blot applications, researchers should optimize protein extraction methods based on the cellular localization of interest (nuclear vs. cytoplasmic fractions). Standard protocols using RIPA buffer with protease inhibitors are generally effective for total protein extraction. For ELISA applications, antibody pairs should be validated for specificity and sensitivity, with standard curves established using recombinant IME4 protein to ensure accurate quantification.

What species reactivity is available for commercial IME4 antibodies?

Commercial IME4 antibodies exhibit reactivity across multiple species including Drosophila, Saccharomyces, and bacterial models . This cross-species reactivity reflects the evolutionary conservation of IME4/METTL3 function across phylogenetic boundaries and enables comparative studies between model organisms.

When using IME4 antibodies across species, researchers should validate cross-reactivity empirically rather than relying solely on manufacturer claims. This validation should include positive and negative controls from each target species. Sequence alignment of the antibody epitope region across species can help predict potential cross-reactivity, but functional validation remains essential, particularly when studying distantly related organisms.

How should researchers validate IME4 antibody specificity?

Rigorous validation of IME4 antibody specificity is crucial for generating reliable research data. A comprehensive validation approach should include:

• Knockout/knockdown controls: Utilizing CRISPR-Cas9 knockout or siRNA knockdown samples to confirm absence or reduction of signal in Western blot or immunostaining applications.

• Recombinant protein standards: Testing antibody against purified recombinant IME4 protein alongside potential cross-reactive family members.

• Peptide competition assays: Pre-incubating the antibody with excess immunizing peptide to demonstrate signal reduction.

• Multiple antibody concordance: Comparing results using antibodies targeting different epitopes of IME4.

• Cross-species validation: For antibodies claiming multi-species reactivity, confirming specific binding in each species of interest.

This multi-faceted approach provides stronger evidence of specificity than single validation methods. Researchers should document these validation steps in their methods sections to strengthen the reliability of their findings.

What are the optimal conditions for Western Blot detection of IME4?

Optimizing Western Blot protocols for IME4 detection requires careful consideration of several parameters:

For challenging samples, researchers should consider modifications such as extended transfer times for large proteins, gradient gels for better resolution, or specialized membrane types to improve protein retention and detection sensitivity.

How does IME4/METTL3 function in m6A RNA modification pathways?

IME4/METTL3 serves as the catalytic component of the m6A methyltransferase complex, which introduces N6-methyladenosine modifications into mRNA. This epigenetic RNA modification influences RNA metabolism, including splicing, export, translation, and degradation. When investigating these pathways using antibody-based techniques, researchers should consider:

• Complex formation analysis: Co-immunoprecipitation with IME4 antibodies can identify interaction partners including METTL14, WTAP, and other regulatory proteins.

• Subcellular localization studies: Immunofluorescence using IME4 antibodies can track protein localization under different cellular conditions or stresses.

• Activity correlation: Combining IME4 protein detection with m6A RNA methylation assays to correlate enzyme levels with catalytic activity.

• Post-translational modification detection: Using modification-specific antibodies alongside general IME4 antibodies to assess how modifications affect complex formation and activity.

These approaches enable researchers to investigate the functional relationships between IME4 protein levels, localization, complex formation, and m6A deposition across different physiological and pathological contexts.

What methodological considerations apply when using IME4 antibodies for chromatin immunoprecipitation (ChIP)?

While IME4/METTL3 primarily functions in RNA modification, evidence suggests potential chromatin associations. Researchers employing ChIP with IME4 antibodies should address these technical considerations:

• Crosslinking optimization: Since IME4 may interact with chromatin indirectly through RNA intermediates, test both formaldehyde (protein-DNA) and UV (protein-RNA-DNA) crosslinking methodologies.

• DNase/RNase treatment controls: Include parallel samples treated with nucleases to distinguish direct DNA binding from RNA-mediated chromatin association.

• Antibody performance testing: Evaluate antibodies specifically for ChIP applications, as good Western blot antibodies may not perform well in ChIP contexts.

• Sequential ChIP approaches: Consider sequential ChIP (ChIP-reChIP) using antibodies against known chromatin-associated partners to identify specific IME4-containing complexes on chromatin.

• Control regions selection: Include negative control regions without expected IME4 binding alongside positive controls based on literature or preliminary data.

How can researchers differentiate between IME4 isoforms using antibody-based techniques?

Distinguishing between IME4 isoforms presents significant technical challenges requiring specialized antibody approaches:

• Isoform-specific antibody generation: Design antibodies targeting unique sequences present in only one isoform, typically in alternatively spliced regions.

• Two-dimensional gel electrophoresis: Combine isoelectric focusing with SDS-PAGE followed by western blotting to separate isoforms with subtle size differences but distinct charge profiles.

• Immunoprecipitation followed by mass spectrometry: Use pan-IME4 antibodies for immunoprecipitation, then analyze the precipitated proteins by mass spectrometry to distinguish isoform-specific peptides.

• Isoform-selective knockdown validation: Validate isoform-specific antibodies using selective knockdown of individual isoforms via isoform-targeted siRNAs.

• Recombinant isoform standards: Generate purified recombinant proteins for each isoform to serve as positive controls and quantification standards.

This multi-faceted approach can help researchers accurately identify which IME4 isoforms are expressed in specific tissues or cell types, and how their expression patterns change under different experimental conditions.

What are the technical considerations for multiplex immunofluorescence studies involving IME4?

Multiplex immunofluorescence incorporating IME4 detection alongside other proteins of interest requires careful experimental design:

• Antibody species selection: Choose primary antibodies from different host species to avoid cross-reactivity in multiplex detection.

• Sequential staining protocols: For antibodies from the same species, consider sequential staining with complete blocking steps between cycles.

• Spectral overlap mitigation: Select fluorophores with minimal spectral overlap and apply appropriate compensation during image acquisition and analysis.

• Steric hindrance assessment: Evaluate whether multiple antibodies targeting proteins in the same complex may interfere with each other's binding.

• Controls for each fluorophore: Include single-stained controls for each antibody-fluorophore combination to verify specificity in the multiplex context.

Researchers should also consider the subcellular localization patterns of IME4 (both nuclear and cytoplasmic) when designing co-localization studies with other proteins of interest. Appropriate confocal microscopy settings and deconvolution algorithms may be necessary to accurately assess co-localization at the subcellular level.

How can researchers investigate IME4 function in relation to DNA damage response pathways?

Given IME4's reported involvement in DNA damage pathways, researchers might employ these methodological approaches:

• Co-immunoprecipitation studies: Use IME4 antibodies to pull down protein complexes before and after DNA damage induction, followed by mass spectrometry or Western blotting for DNA repair factors.

• Proximity ligation assays: Employ in situ proximity ligation to visualize and quantify interactions between IME4 and DNA damage response proteins at the single-cell level.

• ChIP-sequencing after damage: Perform ChIP-seq with IME4 antibodies following DNA damage to identify potential recruitment to damage sites.

• Immunofluorescence co-localization: Combine IME4 antibodies with antibodies against DNA damage markers (γH2AX, 53BP1) to assess recruitment dynamics to damage sites.

• Functional rescue experiments: In IME4 knockdown/knockout systems, assess whether wild-type vs. mutant IME4 expression can rescue DNA damage sensitivity phenotypes.

These approaches can help delineate whether IME4's role in DNA damage response is direct (through protein-protein interactions with repair machinery) or indirect (through m6A modification of RNAs encoding repair factors).

What strategies can address weak or inconsistent IME4 antibody signals?

Researchers encountering weak or variable IME4 detection should systematically troubleshoot with these approaches:

• Sample preparation optimization: Ensure complete lysis and protein extraction with protease inhibitors, particularly for nuclear proteins.

• Antibody titration: Test a concentration gradient of primary antibody to identify optimal signal-to-noise ratio.

• Signal amplification methods: Consider tyramide signal amplification or polymer-based detection systems for immunohistochemistry applications.

• Epitope retrieval evaluation: For fixed tissue samples, compare heat-induced and enzymatic epitope retrieval methods.

• Alternative antibody evaluation: Test antibodies recognizing different epitopes of IME4, as some regions may be masked by protein interactions or modifications.

• Protein expression verification: Confirm IME4 expression in your specific cell type or tissue by RT-qPCR before troubleshooting antibody detection.

Researchers should also consider whether their experimental treatments might affect IME4 stability or expression levels, which could result in genuine biological variability rather than technical inconsistency.

How can researchers verify antibody specificity when studying IME4 across diverse experimental models?

When applying IME4 antibodies across different species or experimental systems, verification of specificity becomes particularly important:

• Epitope conservation analysis: Perform sequence alignment of the antibody epitope region across species of interest to predict potential cross-reactivity.

• Species-specific positive controls: Include known positive samples from each species in validation experiments.

• Heterologous expression validation: Express tagged IME4 from different species in a control cell line to verify antibody detection.

• Pre-absorption controls: Pre-incubate antibody with recombinant IME4 protein from the species of interest to confirm specific binding.

• Parallel detection methods: Combine antibody-based detection with orthogonal methods like mass spectrometry to confirm target identity.

This systematic approach helps ensure that detected signals genuinely represent IME4 rather than non-specific binding or cross-reactivity with other proteins, particularly important when working with less commonly studied model organisms.

How should researchers interpret variations in IME4 detection between different sample types?

Interpreting differences in IME4 levels between sample types requires careful consideration of both biological and technical factors:

• Cell-type specific expression: IME4/METTL3 expression varies naturally between cell types, with higher expression often observed in proliferating cells.

• Subcellular distribution changes: IME4 may shuttle between nuclear and cytoplasmic compartments under different conditions, affecting detection in fractionated samples.

• Post-translational modifications: Modifications like phosphorylation may affect antibody binding or protein stability in different physiological states.

• Sample preparation differences: Extraction efficiency may vary between tissue types due to differences in protein-protein interactions or structural components.

• Isoform variation: Different tissues may express varying ratios of IME4 isoforms, potentially affecting detection depending on the antibody's epitope.

When reporting such variations, researchers should acknowledge these potential confounding factors and employ complementary techniques (e.g., RT-qPCR for mRNA levels) to strengthen interpretation of protein-level changes.

What are the considerations for quantitative analysis of IME4 in immunohistochemistry or immunofluorescence?

Quantitative analysis of IME4 staining in tissue sections requires methodological rigor:

• Standardized staining protocols: Maintain consistent fixation, antigen retrieval, antibody concentration, and development times across all samples.

• Appropriate controls: Include positive and negative controls in each staining batch, along with isotype controls to assess non-specific binding.

• Blinded analysis: Conduct scoring or quantification blinded to experimental conditions to prevent bias.

• Digital image analysis validation: If using automated quantification, validate algorithms against manual scoring by multiple observers.

• Spatial context consideration: Report both intensity and localization patterns, as IME4 function may be influenced by its subcellular distribution.

For multiplexed studies, additional considerations include spectral unmixing to address fluorophore bleed-through and standardization of co-localization metrics when assessing IME4 interaction with other proteins of interest.